Udenyca Onbody is a preferred pegfilgrastim product

We’re making some changes to our UnitedHealthcare commercial plans medical benefits as part of our effort to give members access to high-quality products at the lowest possible costs.

On Dec. 26, 2023, the U.S. Food and Drug Administration approved Udenyca Onbody™, an on-body injector (OBI) presentation of Udenyca®. It can be administered on the same day after chemotherapy to decrease the possibility of infection from febrile neutropenia.

With this approval, Udenyca Onbody is now a preferred pegfilgrastim product, similar to Udenyca, Neulasta® and Neulasta Onpro®.

Prior authorization

We require prior authorization for pegfilgrastim products and will review requests according to our White Blood Cell Colony Stimulating Factor Medical Benefit Drug Policy.

You can submit a prior authorization request through the UnitedHealthcare Provider Portal:

• From any page on UHCprovider.com, select Sign In at the top-right corner 
      — Enter your One Healthcare ID 
• New users who don’t have a One Healthcare ID: Visit UHCprovider.com/access to get started
• From the left-hand tabs, select Prior Authorizations & Notifications. Then, click “Create a new request.”
• Select the appropriate prior authorization type from the dropdown
• Enter the required information and click Continue

Additional information

Members currently approved for pegfilgrastim treatment with non-preferred products through their medical benefit may continue their treatment for the duration of their authorization. Members who are new to pegfilgrastim therapy must try or demonstrate intolerance to the preferred pegfilgrastim products before we consider coverage for non-preferred pegfilgrastim products.

Questions?

If you have questions, please email us at pharmacy_news@uhc.com.

PCA-1-24-00559-Clinical-NN_03112024